{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Cassava Sciences, Inc."},"Symbol":{"label":"Symbol","value":"SAVA"},"Address":{"label":"Address","value":"7801 N. CAPITAL OF TEXAS HIGHWAY,SUITE 260 SUITE 300, BUILDING 1, AUSTIN, Texas, 78731, United States"},"Phone":{"label":"Phone","value":"+1 512 501-2444"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms."},"CompanyUrl":{"label":"Company Url","value":"https://www.cassavasciences.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"George B. Thornton","title":"Senior Vice President-Technology"},{"name":"James W. Kupiec","title":"Chief Medical Officer"},{"name":"Michael Zamloot","title":"Senior Vice President-Technical Operations"},{"name":"Richard Jon Barry","title":"President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}